Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Ironwood Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 267

Market Cap: $782.7M

Website

Introduction: Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Clinical Trials

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Phase 2

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Matching Placebo
Drug: IW-3718
Drug: PPI

First Posted Date: 2015-12-22

Last Posted Date: 2019-10-15

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 282

Registration Number: NCT02637557

Locations: 🇺🇸
IW-3718 Investigator, Lynchburg, Virginia, United States

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Phase 2

Completed

Conditions: Irritable Bowel Syndrome With Constipation

Interventions: Drug: Linaclotide
Drug: Matching Placebo

First Posted Date: 2015-09-24

Last Posted Date: 2020-04-24

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 759

Registration Number: NCT02559206

Locations: 🇺🇸
Ironwood Investigational Site, La Crosse, Wisconsin, United States

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Phase 3

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Matching Placebo
Drug: Linaclotide

First Posted Date: 2014-11-14

Last Posted Date: 2017-06-15

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 1223

Registration Number: NCT02291679

Locations: 🇺🇸
Ironwood Investigational Site, La Crosse, Wisconsin, United States

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

Phase 2

Completed

Conditions: Diabetic Gastroparesis

Interventions: Drug: IW-9179
Drug: Matching Placebo

First Posted Date: 2014-11-13

Last Posted Date: 2016-12-05

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 90

Registration Number: NCT02289846

Locations: 🇺🇸
Ironwood Investigational Site, Ogden, Utah, United States

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Phase 2

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Matching Placebo
Drug: IW-3718

First Posted Date: 2014-01-09

Last Posted Date: 2016-08-01

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 93

Registration Number: NCT02030925

Locations: 🇺🇸
Ironwood Investigational Site, South Ogden, Utah, United States

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Phase 2

Terminated

Conditions: Dyspepsia
Functional Gastrointestinal Disorders

Interventions: Drug: IW-9179
Drug: Placebo

First Posted Date: 2012-10-23

Last Posted Date: 2014-03-19

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 10

Registration Number: NCT01712412

Locations: 🇧🇪
AZ Sint-Lucas Brugge, Brugge, Belgium
🇧🇪
Antwerp University Hospital, Edegem, Belgium
🇧🇪
Z.O.L. - Campus St. Jan, Genk, Belgium

and more 12 locations

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

Phase 2

Completed

Conditions: Healthy

Interventions: Drug: IW-6118
Drug: Matching Placebo
Drug: Naproxen Sodium

First Posted Date: 2010-04-20

Last Posted Date: 2022-08-11

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 90

Registration Number: NCT01107236

Locations: 🇺🇸
Ironwood Investigational Site, Salt Lake City, Utah, United States

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Phase 3

Completed

Conditions: Irritable Bowel Syndrome With Constipation

Interventions: Drug: Linaclotide or Matching Placebo

First Posted Date: 2009-07-14

Last Posted Date: 2013-11-05

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 805

Registration Number: NCT00938717

Locations: 🇺🇸
Ironwood Investigational Site, Milwaukee, Wisconsin, United States

Trial of Linaclotide in Patients With Chronic Constipation

Phase 3

Completed

Conditions: Chronic Constipation

Interventions: Drug: Linaclotide
Drug: Matching Placebo

First Posted Date: 2008-08-08

Last Posted Date: 2013-01-30

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 643

Registration Number: NCT00730015

Locations: 🇺🇸
Ironwood Investigational Site, Milwaukee, Wisconsin, United States

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Phase 3

Completed

Conditions: Irritable Bowel Syndrome With Constipation
Chronic Constipation

Interventions: Drug: Linaclotide

First Posted Date: 2008-08-08

Last Posted Date: 2018-02-19

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Target Recruit Count: 1743

Registration Number: NCT00730171

Locations: 🇺🇸
Ironwood Investigational Site, Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy